evidence: An initial inspection by the company found no major damage to its medicine manufacturing areas, and all 3,200 local employees are safe and accounted for. Pfizer Chairman and CEO Dr. Albert Bourla said staff are rushing products to nearby sites for storage and identifying sources to rapidly replace raw materials lost in the storm. The drug company says it is also exploring alternative manufacturing locations across its U.S. network to fill gaps in production while the North Carolina site remains closed for repairs. The FDA’s initial analysis identified fewer than 10 drugs for which Pfizer’s North Carolina plant is the sole source for the U.S. market, Califf said. The Rocky Mount plant produces anesthesia and many other drugs needed for surgeries but does not make or store Pfizer’s COVID-19 vaccine or the Comirnaty and Paxlovid treatments. Medications produced at that facility alone account for nearly 8 percent of all sterile injectables used in U.S. hospitals, Pfizer said on its website. The FDA said it will complete in the coming days a more extensive evaluation of the products that might be affected and the current domestic supply of those medications.